Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Tecentriq), avelumab (Bavencio), obinutuzumab (Gazyvaro), and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. The company also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.

Bio-Rad’s range of ready-made anti-biotherapeutic antibodies enables the development of robust and reliable bioanalytical assays against marketed biologic drugs. The new anti-idiotypic antibodies are suitable for pharmacokinetic (PK) and antidrug-antibody assays for atezolizumab, avelumab, obinutuzumab, and ocrelizumab, enabling therapeutic drug monitoring for innovator and biosimilar products. 

The anti-MMAE antibody range supports bioanalysis of antibody-drug conjugates (ADCs) carrying MMAE as payload. MMAE is a potent antimitotic agent that inhibits cell division. Due to its toxicity, MMAE is not used as a drug itself, but instead forms the payload component of ADCs. Bio-Rad’s new anti-MMAE biotherapeutic antibodies enable the development of sensitive assays for both ADCs incorporating the toxin, or the toxin itself.

“Bio-Rad’s extensive range of anti-biotherapeutic antibodies offers an effective solution to drug-specific bioanalytical assay development, enabling design of selective, sensitive, and reliable PK and ADA assays,” said John Cardone, Marketing Manager, Life Science Group, Bio-Rad. “Introduction of the new drug-specific and MMAE anti-biotherapeutic antibodies further expands the utility of our market-leading portfolio of over 200 anti-idiotypic antibodies, providing our customers with new and innovative bioanalysis tools to accelerate antibody drug discovery.”  

To learn more about Bio-Rad’s anti-idiotypic antibodies, visit bio-rad.com/biotherapeutic-antibodies.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. Products containing SpyTag1, SpyTag3, SpyCatcher1 or SpyCatcher3 and/or their use are covered by the following U.S. patents and/or pending U.S. patent application or their foreign counterparts owned by or under license to Bio-Rad Laboratories, Inc., including, but not limited to, U.S. Patent Nos. 9,547,003, 10,247,727, and 10,527,609. Products containing SpyTag2 or SpyCatcher2 and/or their use are covered by the following U.S. patents and/or pending U.S. patent application or their foreign counterparts owned by or under license to Bio-Rad Laboratories, Inc., including, but not limited to, U.S. Patent Nos. 9,547,003, 10,247,727, 10,527,609, and 11,059,867. 

About Bio-Rad  

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.